| Original language | English |
|---|---|
| Pages (from-to) | 294-295 |
| Number of pages | 2 |
| Journal | Medical Journal of Australia |
| Volume | 205 |
| Issue number | 7 |
| DOIs |
|
| Publication status | Published - 3 Oct 2016 |
Cite this
}
Biosimilars in inflammatory bowel disease : Cost savings are welcome but evidence supporting equivalence of biosimilar and originator drugs is currently limited. / Moore, Gregory T.
In: Medical Journal of Australia, Vol. 205, No. 7, 03.10.2016, p. 294-295.Research output: Contribution to journal › Comment / Debate › Other › peer-review
TY - JOUR
T1 - Biosimilars in inflammatory bowel disease
T2 - Cost savings are welcome but evidence supporting equivalence of biosimilar and originator drugs is currently limited
AU - Moore, Gregory T
PY - 2016/10/3
Y1 - 2016/10/3
UR - http://www.scopus.com/inward/record.url?scp=85016924779&partnerID=8YFLogxK
U2 - 10.5694/mja16.00775
DO - 10.5694/mja16.00775
M3 - Comment / Debate
VL - 205
SP - 294
EP - 295
JO - Medical Journal of Australia
JF - Medical Journal of Australia
SN - 0025-729X
IS - 7
ER -